- •
A significant proportion of patients continue to smoke despite knowing they have chronic obstructive pulmonary disease (COPD).
- •
Smokers with COPD exhibit higher levels of nicotine dependence and have lower self-efficacy and self-esteem, which affects their ability to quit smoking.
- •
The combination of counseling plus pharmacotherapy is the most effective cessation treatment of smokers with COPD.
- •
Because of the high morbidity and mortality of influenza in patients with COPD, annual influenza
Smoking Cessation/Vaccinations
Section snippets
Key points
Smoking cessation in chronic obstructive pulmonary disease
Cigarette smoking is the leading risk factor for chronic obstructive pulmonary disease (COPD) in developed countries and an important contributor to the burden in most societies around the world. Patients with COPD who continue to smoke have a higher prevalence of symptoms persistence, an accelerated decline in lung function, increased exacerbations, and higher mortality rate than nonsmokers.1, 2, 3, 4, 5, 6 Therefore, smoking cessation has been identified as the single most cost-effective and
Smoking prevalence in chronic obstructive pulmonary disease
A significant proportion of patients with COPD continue to smoke despite knowing they have the disease, and as a consequence this behavior has a negative impact on the prognosis and progression of the disease.7
Several cross-sectional worldwide population-based studies have assessed the smoking status (never, former, and current smokers) in different COPD population. The IBERPOC study in Spain reported a prevalence of 15% and 12.8% for patients with COPD who are current and ex-smokers ,
Characteristics of smokers with chronic obstructive pulmonary disease
There are differences in clinical characteristics between smoking patients with and without COPD. Smokers with COPD exhibit higher levels of nicotine dependence, smoke more cigarettes a day, have higher cotinine concentrations, and have less self-efficacy and self-esteem than those without the disease, all of which affect their ability to quit smoking.13,23,24 This does not seem to be due to lack of motivation to quit, which was not different between smokers with and without COPD.24 On the
Smoking diagnosis in chronic obstructive pulmonary disease
The approach to the smoking patient in general should consider the mental situation in which the subject is at the time of consultation, paying attention to 2 aspects intimately linked with tobacco use: motivation and dependence.
Smoking cessation treatments
Several studies have shown that a combination of counseling plus pharmacotherapy is the most effective cessation intervention for smokers with COPD.34, 35, 36, 37
Smoking reduction
Approved smoking cessation medications (NRT, bupropion, and varenicline) in combination with SCC have shown to double or triple quit rates under stringent settings of clinical trials. Nonetheless, relapse is common in the course of a smoking cessation; therefore, harm reduction has been considered as an alternative approach for resistant smokers with COPD or for those who are not ready to quit. This represents a dilemma for many pulmonary physicians and the results of the smoking reduction
E-cigarettes
Recently the use of novel tobacco products, particularly the electronic cigarette (EC) has increased probably due to the presumption that this is associated with less damage, as well as reducing the symptoms of anxiety and withdrawal from tobacco by sharing the same visual and sensory characteristics. Although the potential harm reduction due to switching from conventional cigarettes to EC in patients with COPD has not been studied, the perception exists that they are safer or are an effective
Vaccination in patients with chronic obstructive pulmonary disease
Acute exacerbations are an important cause of morbidity and mortality in patients with COPD. Although COPD exacerbations can be precipitated by factors, including environmental pollution, the most common causes seem to be respiratory tract infections by virus and bacteria (50%–70% of cases). Therefore, preventing exacerbations in patients with COPD is a major objective, and vaccination is accepted as an effective and simple preventive strategy to achieve this goal.64 The most common vaccines
Vaccination rates
Although immunization against influenza is recommended for all patients with COPD by several international health authorities and guidelines, the coverage rates of influenza vaccination for high-risk patients including those with chronic respiratory diseases, remain less than target levels in many countries.65, 66, 67, 68, 69, 70 In the United States coverage of high-risk adults was less than the target of 70% (47.6% for those between 18 and 64 years and 66.7% in adults ≥65 years) in 2014 to
Influenza disease
Influenza are RNA viruses of the family orthomyxoviridae. Influenza A, B, and C are able to infect humans, with influenza A and B being the most common circulating types. Influenza A virus has been divided into subgroups based on the 2 core proteins hemagglutinin (H) and neuraminidase (N). There are at least 18 and 11 subtypes of hemagglutinin and neuraminidase, respectively; however only 3 H proteins (H1, H2, and H3) and 2 N proteins (N1 and N2) have been detected in human.
Influenza is an
Pneumococcal diseases in patients with chronic obstructive pulmonary disease
Streptococcus pneumoniae is an encapsulated gram-positive coccus and a major cause of community-acquired pneumonia (CAP) in adults worldwide, associated with considerable morbidity and mortality.89, 90, 91, 92
Lower respiratory tract infections and COPD are the fourth and the third leading causes of death worldwide in 2016, respectively, and about half of all deaths from lower respiratory infections are attributable to pneumococcal pneumonia.93
A systematic review and meta-analysis reported an
Summary
More than one-third of patients with COPD continue smoking despite knowing that they have the disease and that this behavior has a negative impact on the disease prognosis and progression. Smokers with COPD exhibit higher levels of nicotine dependence and lower self-efficacy and self-esteem, which affects their ability to quit smoking. A combination of counseling plus pharmacotherapy is the most effective cessation treatment of smokers with COPD. Varenicline seems to be the most effective
Disclosure
M. Montes de Oca has stated that she has nothing to disclose.
References (125)
- et al.
Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study
Am J Med
(1999) - et al.
Smoking cessation a critical component of medical management in chronic disease populations
Am J Prev Med
(2007) - et al.
Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study
Lancet
(2005) - et al.
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
Lancet Respir Med
(2018) - et al.
Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial
Lancet
(2016) - et al.
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial
Lancet
(2016) - et al.
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial
Lancet
(2017) - et al.
Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial
Lancet Respir Med
(2018) - et al.
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial
Lancet
(2018) - et al.
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
Lancet Respir Med
(2018)
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol
Respir Med
Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD
Chest
Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support
Chest
Lung function and respiratory symptoms in a 1year randomized smoking cessation trial of varenicline in COPD patients
Respir Med
Smoking cessation in patients with chronic obstructive pulmonary disease: a double- blind, placebo-controlled, randomised trial
Lancet
Smoking cessation effectiveness in smokers with COPD and asthma under real life conditions
Respir Med
Relationship between current smoking, visual CT findings and emphysema index in cigarette smokers
Clin Imaging
A short formof the Fagerström test for nicotine dependence and the heaviness of smokingindex in two adult population samples
Addict Behav
Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial
Chest
Varenicline for long term smoking cessation in patients with COPD
Pulm Pharmacol Ther
E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis
Lancet Respir Med
E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach
Lancet Respir Med
Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline
Chest
ALAT-2014 chronic obstructive pulmonary disease (COPD) clinical practice guidelines: questions and answers
Arch Bronconeumol
Influenza vaccination among Canadians with chronic respiratory disease
Respir Med
Influenza vaccination coverage and related factors among Spanish patients with chronic obstructive pulmonary disease
Vaccine
Compliance with influenza and pneumococcal vaccination among patients with chronic obstructive pulmonary disease consulting their medical practitioners in Catalonia, Spain
J Infect
Prevalence of influenza vaccination in chronic obstructive pulmonary disease patients and impact on the risk of severe exacerbations
Arch Bronconeumol
Treatment of chronic obstructive pulmonary disease in 5 Latin American cities: the PLATINO study
Arch Bronconeumol
Influenza vaccination and risk of respiratory failure in patients with chronic obstructive pulmonary disease: a nationwide population-based case-cohort study
J Microbiol Immunol Infect
The natural history of community-acquired pneumonia in COPD patients: a population database analysis
Respir Med
Invasive pneumococcal disease in patients with an underlying pulmonary disorder
Clin Microbiol Infect
COPD-related morbidity and mortality after smoking cessation: status of the evidence
Eur Respir J
The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations
J Gen Intern Med
Successful smoking cessation in COPD: association with comorbidities and mortality
Pulm Med
Th e effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial
Intern Med
Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study
Am J Respir Crit Care Med
Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study
Chest
Smoking prevalence and cessation characteristics among U.S. adults with and without COPD: findings from the 2011 Behavioral Risk Factor Surveillance System
COPD
Chronic obstructive pulmonary disease in Latin America
Ann Glob Health
Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample
Thorax
Mortality and exacerbations by global initiative for chronic obstructive lung disease groups ABCD: 2011 versus 2017 in the COPDGene® cohort
Chronic Obstr Pulm Dis
Once-daily single-inhaler triple versus dual therapy in patients with COPD
N Engl J Med
Behavioural anti-smoking trial in chronic obstructive pulmonary disease patients
Psychopharmacology (Berl)
Are patients with COPD psychologically distressed?
Eur Respir J
The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD
Scand J Prim Health Care
Time to first cigarette: the best single indicator of tobacco dependence?
Monaldi Arch Chest Dis
Smoking cessation interventions in COPD: a network meta-analysis of randomised trials
Eur Respir J
Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD
Thorax
Smoking cessation for people with chronic obstructive pulmonary disease
Cochrane Database Syst Rev
Cited by (12)
COPD and multimorbidity: recognising and addressing a syndemic occurrence
2023, The Lancet Respiratory MedicineGlobal Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
2023, Archivos de BronconeumologiaCOPD: a still neglected condition
2023, Revue Medicale SuisseCOPD - An Underestimated Disease
2023, PraxisGlobal Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
2023, American Journal of Respiratory and Critical Care Medicine